

Atty. Dkt. No. 041673-2053

Amendments to the Claims:

Please cancel claims 3-5 and 17. Also, please amend claims 1, 2, 6, 9, 12 and 14-16, and add new claims 19-20, as set forth below. This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Presently Amended) A method ~~for delivery to stimulate or support cortical neurons in a subject's brain, the method comprising delivering of a nervous system growth factor composition consisting of brain-derived neurotrophic a therapeutic nervous system growth factor (BDNF) or NT-4/5 to targeted defective, diseased or damaged-neurons in cortical tissues containing trkB receptors, the method comprising delivering a nervous system growth factor composition into one or more delivery sites within the targeted cortical tissues of a subject; wherein contact with the nervous system growth factor ameliorates the defect, disease or damage in the subject's cortical cells, including those in the entorhinal cortex (EC).~~
2. (Currently Amended) The method according to Claim 1, wherein ~~practice of the method produces amelioration of the defect, disease or damage causes an improvement in cognitive function in the treated subject.~~
3. (Cancelled.)
4. (Cancelled.)
5. (Cancelled.)
6. (Currently Amended) The method according to Claim 1, wherein the ~~growth factor BDNF or NT-4/5 is a recombinant protein delivered by *in situ* expression of the growth factor from a recombinant expression vector.~~
7. (Original) The method according to Claim 6, wherein the recombinant expression vector is a lentiviral vector.

Atty. Dkt. No. 041673-2053

8. (Original) The method according to Claim 7, wherein the lentiviral vector is HIV-1.
9. (Currently Amended) The method according to Claim 1, wherein the growth factor composition is delivered by infusion into the entorhinal cortex EC.
10. (Original) The method according to Claim 9, wherein the infusion is accomplished over an extended period of time via a micropump.
11. (Original) The method according to Claim 1, wherein the subject is a human.
12. (Currently Amended) The method according to Claim 11, wherein the human is suffering from Alzheimer's disease, and the disease is ameliorated by stimulation of growth or activity in ~~of~~ neurons in ~~of~~ the entorhinal cortex EC.
13. (Original) The method according to Claim 11, wherein the disease is ameliorated by reversal of deficits in cognitive function associated with the Alzheimer's disease.
14. (Currently Amended) The method according to Claim 1, wherein the ~~targeted defective, diseased or damaged~~ neurons include those in innervate the hippocampal cortex.
15. (Currently Amended) The method according to Claim 1, wherein the ~~defective, diseased or damaged~~ neurons include those in innervate the frontal cortex, parietal cortex temporal cortex or visual cortex.
16. (Currently Amended) The method according to Claim 1, wherein the subject is aged. ~~defect or disease in, or damage to, the neurons is the result of aging~~.
17. (Cancelled).
18. (Previously Presented) The method according to Claim 6, wherein the recombinant expression vector is an adeno-associated vector.

Please add the following new claims:

Atty. Dkt. No. 041673-2053

19. (New) The method according to Claim 1, wherein the stimulation or support is of entorhinal cortex neurons.

20. (New) The method according to Claim 1, wherein the stimulation or support is of hippocampal neurons.